Healthcare · NSE: SENORES
Senores Pharmaceuticals
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 29 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹5,286Cr
- P/E
- 38.2×
- 1Y return
- +47.08%
- From 52W high
- −28.2%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 192 | 162 | +18.9% | 180 | +6.7% |
| EBITDA | 58 | 50 | +16.5% | 54 | +7.3% |
| EBITDA margin | 30.0% | 30.6% | -63 bps | 29.8% | +15 bps |
| PBTProfit before tax | 48 | 41 | +17.1% | 39 | +20.6% |
| Net profit | 39 | 32 | +22.0% | 31 | +28.6% |
| EPS (₹) | 8.82 | 6.54 | +34.9% | 6.60 | +33.6% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Regulated markets: All 64 approved ANDAs expected to be commercialised in six to eight quarters
Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
Regulated markets: All 64 approved ANDAs expected to be commercialised in six to eight quarters
“So, as we move forward, more and more products coming in next few quarters, six, eight quarters that we've stated, we expect our 64 of 64 will be commercialized as we speak from the portfolio that we have.”
Regulated markets: 84 ANDAs expected to be commercialised over the next three to four years
Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
Regulated markets: 84 ANDAs expected to be commercialised over the next three to four years
“So, if hindsight if you think about it, in next three to four years, we have 41 plus 43, 84 ANDAs that are going to be commercialized in next two to three to four years timeframe.”
Zoraya: 14 ANDAs planned to launch under Zoraya in FY27
Swapnil Shah · Promoter and Managing Director · Q&A · p. 18
Zoraya: 14 ANDAs planned to launch under Zoraya in FY27
“But high level that I can say, we have 14 ANDAs that are going to be that are planned to launch under Zoraya, in as Zoraya becomes live.”
Emerging markets: Full-year emerging market margin expected at lower to mid-teens
Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
Emerging markets: Full-year emerging market margin expected at lower to mid-teens
“So full year we expect we'll be about mid-teens to low lower-teens of margin on emerging markets”
MD confirms the stated FY27 guidance is maintained and expects to achieve it
Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
MD confirms the stated FY27 guidance is maintained and expects to achieve it
“Yes. So if you can see, we at H1 FY26 to H1 FY27, our EBITDA is already grown by 58%. So, we expect with Zoraya, Amerisyn coming in and the further launch pipelines, very visible pipeline that we have today for next quarter, I mean coming quarter and a quarter after, January we expect to achieve our guidance that we stated.”
More figures from the call
“So yes, overall, I think the bottom-line growth this year should be more than the top-line growth. It's just an indicative statement of about 50-odd percent is what Swapnil has said based on our internal calculations.”
“We are expected to launch about four to five controlled substance within this year before March 31st, 2027.”
“We've launched couple of products in current quarter and this quarter also, Q3 FY27, we expect three to four new ANDA approvals to come in and corresponding supplement ANDAs, so sANDA and the strengths that we talk about, it's that's about 12 to 15 sANDAs are expected to approve on our portfolio.”
In short
- 01FY27 guidance kept at 30% to 40% revenue growth and 50% to 60% PAT growth.
- 02Around 25% annual growth expected for 2 to 3 years after FY27.
- 03FY27 EBITDA margin aimed at 30% or a little higher.
- 04Q2 FY27 revenue was Rs 192 crore, up 25%; EBITDA Rs 58 crore at 30% margin.
- 05Amerisyn and Zoraya expected to start sales this quarter; their Rs 4 crore Q2 cost had no revenue.
- 06Apnar plant to have four lines by March 2027 and about Rs 100 crore revenue in FY27.
- 07Emerging market margin fell in Q2 on beta-lactam orders; full year seen at lower to mid-teens.
Capex
H1 FY27 capex about Rs 46 crore
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
H1 FY27 capex about Rs 46 crore
“Our capex for H1 of FY27 is approximately INR46 crores.”
Capacity
Apnar: Apnar to have four commercial lines by March 31, 2027; third line being installed
4linesSwapnil Shah · Promoter and Managing Director · Q&A · p. 6
Apnar: Apnar to have four commercial lines by March 31, 2027; third line being installed
4lines“From the lines perspective, as I said, we have plans to have total four commercial lines at Apnar facility by March 31st, 2027. Two lines were already there. Third line, as we speak are getting installed and the fourth will be done before March 2027.”
Apnar: Apnar capacity to be about 1.2 billion units with four lines
Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
Apnar: Apnar capacity to be about 1.2 billion units with four lines
“So, with that, we'll have about four commercial lines with a total production capacity of about 1.2 billion units from Apnar facility”
Apnar: Apnar running at 90% to 100% capacity, mostly for validation
Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
Apnar: Apnar running at 90% to 100% capacity, mostly for validation
“So Apnar, we are operating at almost 90% to 100% of the capacity, but large part of our capacity is all being used for validation for our product launches.”
Apnar: Over 50% of Apnar work is validation; full use not yet in revenue
Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
Apnar: Over 50% of Apnar work is validation; full use not yet in revenue
“But the complete utilization is not generating in the revenue as yet. Since there's lot of validation work, more than 50% validation work is going on.”
Emerging markets: Pre-filled syringe line installed to support GLP-1 and other products
Swapnil Shah · Promoter and Managing Director · p. 4
Emerging markets: Pre-filled syringe line installed to support GLP-1 and other products
“On emerging markets, we with installation of pre-filled syringe line, we will support our growth for GLP-1 and other products.”
Segments
Emerging markets: Emerging market margin expected back to Q4 FY26 level from current quarter
Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
Emerging markets: Emerging market margin expected back to Q4 FY26 level from current quarter
“So, we because of that, that's a little bit of margin decline on the emerging market that you have seen in this quarter, but from current quarter onwards again you will it will go back to what we were in Q4 FY26.”
Emerging markets: Emerging market revenue grew about 21% in Q2 and 25% in H1 FY27
Swapnil Shah · Promoter and Managing Director · p. 4
Emerging markets: Emerging market revenue grew about 21% in Q2 and 25% in H1 FY27
“Moving to emerging market business, revenue grew by approximately 21% in Q2 and 25% in H1 FY27.”
Regulated markets: Regulated market grew 28% in Q2 and 34% in H1 FY27
Swapnil Shah · Promoter and Managing Director · p. 3
Regulated markets: Regulated market grew 28% in Q2 and 34% in H1 FY27
“Our regulated market business continued to deliver strong growth, registering Y-o-Y growth of 28% in Q2 and 34% in H1 FY27, driven by portfolio expansion and differentiated sales and distribution channels.”
CDMO CMO: Three CDMO/CMO ANDAs covering 12 strengths commercialised
3ANDAsSwapnil Shah · Promoter and Managing Director · p. 3
CDMO CMO: Three CDMO/CMO ANDAs covering 12 strengths commercialised
3ANDAs“On CMO CDMO front, we have commercialized three ANDAs covering 12 strengths.”
Meaningful acceleration expected in H2 FY27
Swapnil Shah · Promoter and Managing Director · p. 3
Meaningful acceleration expected in H2 FY27
“Supported by established marketing partnerships, launch readiness and calibrated manufacturing capacities, we expect a meaningful acceleration in H2 FY27.”
Margins and costs
Emerging markets: Emerging market margin fell in Q2 due to large beta-lactam orders
Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
Emerging markets: Emerging market margin fell in Q2 due to large beta-lactam orders
“So, margins have slightly decreased on the emerging market in this quarter because there have been few large orders of beta-lactam products.”
No margin dip expected as subsidiaries go live
Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
No margin dip expected as subsidiaries go live
“But do we expect any margin dip? The answer is no, but we will see, we'll continue to monitor and see how the margins progress on because of those two subsidiaries coming live.”
Amerisyn, Zoraya: Subsidiary costs not expected to rise from Rs 4 crore to Rs 20 crore
Swapnil Shah · Promoter and Managing Director · Q&A · p. 13
Amerisyn, Zoraya: Subsidiary costs not expected to rise from Rs 4 crore to Rs 20 crore
“Yes, but as I said, you know, going forward, do I do we expect that INR4 crores to become INR20 crores? The answer is no, right?”
Regulated markets: Regulated market margin not expected to go down
Swapnil Shah · Promoter and Managing Director · Q&A · p. 16
Regulated markets: Regulated market margin not expected to go down
“Do we expect it to go down? The answer is no, if that is the question that you'll be asking.”
Operating leverage expected to improve margins as revenue scales
Swapnil Shah · Promoter and Managing Director · p. 4
Operating leverage expected to improve margins as revenue scales
“As revenues scale up, we expect to benefit from operating leverage and a corresponding improvement in our margin profile.”
Debt and working capital
Operating cash flow of Rs 38 crore in H1 FY27
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
Operating cash flow of Rs 38 crore in H1 FY27
“On the balance sheet front, we have continued to make steady progress in improving cash generation from operations, with operating cash flow reaching INR38 crores in H1 of financial year 2027.”
Working capital days and receivable days improved
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
Working capital days and receivable days improved
“We have also strengthened our focus on working capital efficiency with a significant improvement in working capital days and the receivable days.”
Unbilled revenue due beyond one year is 8% to 9% of the total
Deval Shah · Whole Time Director and Chief Financial Officer · Q&A · p. 12
Unbilled revenue due beyond one year is 8% to 9% of the total
“It will not be more than 10%. It will be 8% or 9% of the total.”
Unbilled revenue rose as big products shipped in September
Deval Shah · Whole Time Director and Chief Financial Officer · Q&A · p. 12
Unbilled revenue rose as big products shipped in September
“And hence it has added to my accrued income because that those will be sold start the distributor will start selling it in this quarter.”
Acquisitions and new business
Regulated markets: Three sANDAs commercialised; new ANDA approved this quarter to launch in Q3
Swapnil Shah · Promoter and Managing Director · p. 3
Regulated markets: Three sANDAs commercialised; new ANDA approved this quarter to launch in Q3
“Out of this new approvals, we have commercialized three sANDA and the new ANDA where we got approval this quarter will be launched in FY Q3 2026.”
Amerisyn, Zoraya: Amerisyn and Zoraya expected to start contributing from H2 FY27
Swapnil Shah · Promoter and Managing Director · p. 4
Amerisyn, Zoraya: Amerisyn and Zoraya expected to start contributing from H2 FY27
“Over and above this, Amerisyn and Zoraya are expected to start contributing from H2 FY27, providing an additional growth driver with significant scale-up potential over the coming years.”
Amerisyn, Zoraya: More meaningful ramp-up of new ventures expected from FY28
Swapnil Shah · Promoter and Managing Director · p. 4
Amerisyn, Zoraya: More meaningful ramp-up of new ventures expected from FY28
“With these ventures are expected to begin contributing in H2 FY27, a more meaningful ramp- up is anticipated from FY28 onwards.”
Amerisyn: Amerisyn business expected to start within 10 to 15 days
Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
Amerisyn: Amerisyn business expected to start within 10 to 15 days
“So Amerisyn we expect business to commence any moment now, maybe this week we don't know, but within next 10 to 15 days.”
Zoraya: Zoraya about a month to 45 days away; both aimed to start this quarter
Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
Zoraya: Zoraya about a month to 45 days away; both aimed to start this quarter
“Zoraya maybe another month away, I would say worst case about 45 days from today. But we expect both to commercialize within this quarter that's the goal.”
Management
Talati & Talati appointed as joint auditor
Sanjay Majmudar · Chairman · Q&A · p. 11
Talati & Talati appointed as joint auditor
“They are associated with very large companies and after evaluating various options, we felt it's a good choice to have a bigger and more reputed firm as a joint auditor”
One-offs
Amerisyn, Zoraya: Q2 and H1 include Zoraya and Amerisyn setup costs with no revenue
Swapnil Shah · Promoter and Managing Director · p. 4
Amerisyn, Zoraya: Q2 and H1 include Zoraya and Amerisyn setup costs with no revenue
“It is important to note that Q2 and H1 performance includes the initial setup and operating costs for Zoraya and Amerisyn, which were recognized in the P&L without any corresponding revenue contribution.”
Amerisyn, Zoraya: About Rs 4 crore of Zoraya and Amerisyn expenses this quarter
Swapnil Shah · Promoter and Managing Director · Q&A · p. 13
Amerisyn, Zoraya: About Rs 4 crore of Zoraya and Amerisyn expenses this quarter
“So, we have incurred about INR4 crores of expenses pertaining to Zoraya and Amerisyn this quarter.”
Risks
Apnar: Apnar FDA inspection concluded with one minor procedural 483
Swapnil Shah · Promoter and Managing Director · p. 4
Apnar: Apnar FDA inspection concluded with one minor procedural 483
“As everybody knows, recently we concluded a successful FDA inspection at our Apnar facility with one minor procedural 483 that was received.”
Regulated markets: Acquired ANDAs take 3 to 12 months to move to own facility
Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
Regulated markets: Acquired ANDAs take 3 to 12 months to move to own facility
“So that's a time lag of 3 to 12 months, depending upon what regulatory pathway you file the products in, right?”
Regulated markets: Launches to be judged over 6 to 12 months; many steps outside company control
Sanjay Majmudar · Chairman · Q&A · p. 17
Regulated markets: Launches to be judged over 6 to 12 months; many steps outside company control
“And it can't happen at, you know, divide by the number of quarters. It has to be looked at on a more broader time frame of maybe 6 to 12 months, because many things are not under our control.”
Other
Q2 FY27 revenue from operations Rs 192 crore, up 25% year on year
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
Q2 FY27 revenue from operations Rs 192 crore, up 25% year on year
“Starting with the quarterly performance, the consolidated revenue from operations for Q2 FY27 stood at INR192 crores, which as Swapnil said is the highest for us, reflecting a very healthy growth of 25% Y-o-Y.”
Q2 EBITDA Rs 58 crore, up 38%; EBITDA margin 30%, up 290 bps
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
Q2 EBITDA Rs 58 crore, up 38%; EBITDA margin 30%, up 290 bps
“Consolidated EBITDA for Q2 2027 stood at INR58 crores, growing by 38% Y-o-Y and EBITDA margin stood at 30%, which improved by 290 bps year-on-year.”
Q2 PAT about Rs 36.6 crore, up 22% year on year
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
Q2 PAT about Rs 36.6 crore, up 22% year on year
“Profit after tax for the quarter grew by 22% Y-o-Y and came to around INR36.6 crores.”
H1 FY27 revenue Rs 372.5 crore, up 30%
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
H1 FY27 revenue Rs 372.5 crore, up 30%
“Coming to the half-yearly performance, consolidated revenue for H1 grew strongly by 30% Y-o-Y and came to INR372.5 crores.”
H1 EBITDA Rs 111 crore, up 58%; margin almost 30%, up about 530 bps
Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
H1 EBITDA Rs 111 crore, up 58%; margin almost 30%, up about 530 bps
“Consolidated EBITDA for H1 stood at INR111 crores, showing a robust growth of 58% Y-o-Y and EBITDA margin stood at almost 30% in H1 FY27, reflecting a strong improvement of around 530 bps Y-o-Y.”
Sources
- Earnings call transcript, Q2 FY27 Filed 5 Nov 2026 · 19 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

